TREATMENT
Combination therapy targets KRAS G12C mutation in metastatic CRCThe Lancet Oncology published results showing encouraging antitumor activity of ifebemtinib combined with garsorasib in previously treated patients whose metastatic colorectal cancer harbors the KRAS G12C mutation. (The Manila Times)